CrossrefInfokarte
Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer, Real-World Data from a Low-Resourced Country
ImmunoTargets and Therapy · 2024-09 · Volume 13 · 501-512
DOI: 10.2147/itt.s479153 ↗Abstract
Kein Abstract verfügbar.
EUVIMED